Literature DB >> 11025613

Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy.

P Lefterova, F Schakowski, P Buttgereit, C Scheffold, D Huhn, I G Schmidt-Wolf.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025613

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme.

Authors:  Prachya Vichchatorn; Adisak Wongkajornsilp; Sawang Petvises; Sumalee Tangpradabkul; Samart Pakakasama; Suradej Hongeng
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

2.  Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.

Authors:  Suradej Hongeng; Sawang Petvises; Surapon Worapongpaiboon; Busaba Rerkamnuaychoke; Samart Pakakasama; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.

Authors:  Weng-Chee Chan; Yeh-Ching Linn
Journal:  Cytotechnology       Date:  2014-12-07       Impact factor: 2.058

Review 4.  Cytokine-induced NK-like T cells: from bench to bedside.

Authors:  Yeh Ching Linn; Kam M Hui
Journal:  J Biomed Biotechnol       Date:  2010-03-30

Review 5.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

Review 6.  Innovative Clinical Perspectives for CIK Cells in Cancer Patients.

Authors:  Martino Introna; Fabio Correnti
Journal:  Int J Mol Sci       Date:  2018-01-25       Impact factor: 5.923

Review 7.  Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.

Authors:  Pui Yeng Lam; Michael D Nissen; Stephen R Mattarollo
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.